177 related articles for article (PubMed ID: 22058195)
1. p185(BCR/ABL) has a lower sensitivity than p210(BCR/ABL) to the allosteric inhibitor GNF-2 in Philadelphia chromosome-positive acute lymphatic leukemia.
Mian AA; Metodieva A; Najajreh Y; Ottmann OG; Mahajna J; Ruthardt M
Haematologica; 2012 Feb; 97(2):251-7. PubMed ID: 22058195
[TBL] [Abstract][Full Text] [Related]
2. Allosteric inhibition enhances the efficacy of ABL kinase inhibitors to target unmutated BCR-ABL and BCR-ABL-T315I.
Mian AA; Metodieva A; Badura S; Khateb M; Ruimi N; Najajreh Y; Ottmann OG; Mahajna J; Ruthardt M
BMC Cancer; 2012 Sep; 12():411. PubMed ID: 22985168
[TBL] [Abstract][Full Text] [Related]
3. Overcoming Bcr-Abl T315I mutation by combination of GNF-2 and ATP competitors in an Abl-independent mechanism.
Khateb M; Ruimi N; Khamisie H; Najajreh Y; Mian A; Metodieva A; Ruthardt M; Mahajna J
BMC Cancer; 2012 Nov; 12():563. PubMed ID: 23186157
[TBL] [Abstract][Full Text] [Related]
4. The P190, P210, and P230 forms of the BCR/ABL oncogene induce a similar chronic myeloid leukemia-like syndrome in mice but have different lymphoid leukemogenic activity.
Li S; Ilaria RL; Million RP; Daley GQ; Van Etten RA
J Exp Med; 1999 May; 189(9):1399-412. PubMed ID: 10224280
[TBL] [Abstract][Full Text] [Related]
5. The functional interplay between the t(9;22)-associated fusion proteins BCR/ABL and ABL/BCR in Philadelphia chromosome-positive acute lymphatic leukemia.
Rafiei A; Mian AA; Döring C; Metodieva A; Oancea C; Thalheimer FB; Hansmann ML; Ottmann OG; Ruthardt M
PLoS Genet; 2015 Apr; 11(4):e1005144. PubMed ID: 25919613
[TBL] [Abstract][Full Text] [Related]
6. Reciprocal t(9;22) ABL/BCR fusion proteins: leukemogenic potential and effects on B cell commitment.
Zheng X; Oancea C; Henschler R; Moore MA; Ruthardt M
PLoS One; 2009 Oct; 4(10):e7661. PubMed ID: 19876398
[TBL] [Abstract][Full Text] [Related]
7. Oligomerization inhibition, combined with allosteric inhibition, abrogates the transformation potential of T315I-positive BCR/ABL.
Mian AA; Oancea C; Zhao Z; Ottmann OG; Ruthardt M
Leukemia; 2009 Dec; 23(12):2242-7. PubMed ID: 19798092
[TBL] [Abstract][Full Text] [Related]
8. Pre-B acute lymphoblastic leukemia with b3a2 (p210) and e1a2 (p190) BCR-ABL fusion transcripts relapsing as chronic myelogenous leukemia with a less differentiated b3a2 (p210) clone.
Winter SS; Greene JM; McConnell TS; Willman CL
Leukemia; 1999 Dec; 13(12):2007-11. PubMed ID: 10602422
[TBL] [Abstract][Full Text] [Related]
9. Regulation of the c-jun gene in p210 BCR-ABL transformed cells corresponds with activity of JNK, the c-jun N-terminal kinase.
Burgess GS; Williamson EA; Cripe LD; Litz-Jackson S; Bhatt JA; Stanley K; Stewart MJ; Kraft AS; Nakshatri H; Boswell HS
Blood; 1998 Oct; 92(7):2450-60. PubMed ID: 9746785
[TBL] [Abstract][Full Text] [Related]
10. FTY720, a new alternative for treating blast crisis chronic myelogenous leukemia and Philadelphia chromosome-positive acute lymphocytic leukemia.
Neviani P; Santhanam R; Oaks JJ; Eiring AM; Notari M; Blaser BW; Liu S; Trotta R; Muthusamy N; Gambacorti-Passerini C; Druker BJ; Cortes J; Marcucci G; Chen CS; Verrills NM; Roy DC; Caligiuri MA; Bloomfield CD; Byrd JC; Perrotti D
J Clin Invest; 2007 Sep; 117(9):2408-21. PubMed ID: 17717597
[TBL] [Abstract][Full Text] [Related]
11. Comparison of effects of the tyrosine kinase inhibitors AG957, AG490, and STI571 on BCR-ABL--expressing cells, demonstrating synergy between AG490 and STI571.
Sun X; Layton JE; Elefanty A; Lieschke GJ
Blood; 2001 Apr; 97(7):2008-15. PubMed ID: 11264165
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of crosstalk between Bcr-Abl and PKC signaling by PEITC, augments imatinib sensitivity in chronic myelogenous leukemia cells.
Roy M; Sarkar R; Mukherjee A; Mukherjee S
Chem Biol Interact; 2015 Dec; 242():195-201. PubMed ID: 26456889
[TBL] [Abstract][Full Text] [Related]
13. Genomic mechanisms of p210BCR-ABL signaling: induction of heat shock protein 70 through the GATA response element confers resistance to paclitaxel-induced apoptosis.
Ray S; Lu Y; Kaufmann SH; Gustafson WC; Karp JE; Boldogh I; Fields AP; Brasier AR
J Biol Chem; 2004 Aug; 279(34):35604-15. PubMed ID: 15155749
[TBL] [Abstract][Full Text] [Related]
14. Elevated expression of a subset of interferon inducible genes in primary bone marrow cells expressing p185 Bcr-Abl versus p210 Bcr-Abl by DNA microarray analysis.
Advani AS; Dressman HK; Quiroz M; Taylor GA; Pendergast AM
Leuk Res; 2004 Mar; 28(3):285-94. PubMed ID: 14687624
[TBL] [Abstract][Full Text] [Related]
15. Multiplex in-cell reverse transcription-polymerase chain reaction for the simultaneous detection of p210 and p190 BCR-ABL mRNAs in chronic myeloid leukemia and Philadelphia-positive acute lymphoblastic leukemia cell lines.
Suh SP; Kee SJ; Lim WH; Song JW; Lee SK; Kim JP; Shin JH; Ryang DW
Clin Chem Lab Med; 2000 Sep; 38(9):939-44. PubMed ID: 11097354
[TBL] [Abstract][Full Text] [Related]
16. Comparison of bcr-abl protein expression and Philadelphia chromosome analyses in chronic myelogenous leukemia patients.
Guo JQ; Lian J; Glassman A; Talpaz M; Kantarjian H; Deisseroth AB; Arlinghaus RB
Am J Clin Pathol; 1996 Oct; 106(4):442-8. PubMed ID: 8853030
[TBL] [Abstract][Full Text] [Related]
17. Alternative forms of the BCR-ABL oncogene have quantitatively different potencies for stimulation of immature lymphoid cells.
McLaughlin J; Chianese E; Witte ON
Mol Cell Biol; 1989 May; 9(5):1866-74. PubMed ID: 2747638
[TBL] [Abstract][Full Text] [Related]
18. Analysis of the biologic properties of p230 Bcr-Abl reveals unique and overlapping properties with the oncogenic p185 and p210 Bcr-Abl tyrosine kinases.
Quackenbush RC; Reuther GW; Miller JP; Courtney KD; Pear WS; Pendergast AM
Blood; 2000 May; 95(9):2913-21. PubMed ID: 10779439
[TBL] [Abstract][Full Text] [Related]
19. Cytogenetic characterization of a BCR-ABL transduced mouse cell line.
Rudolph C; Hegazy AN; von Neuhoff N; Steinemann D; Schröck E; Stripecke R; Klein C; Schlegelberger B
Cancer Genet Cytogenet; 2005 Aug; 161(1):51-6. PubMed ID: 16080957
[TBL] [Abstract][Full Text] [Related]
20. Changes associated with the development of resistance to imatinib (STI571) in two leukemia cell lines expressing p210 Bcr/Abl protein.
Scappini B; Gatto S; Onida F; Ricci C; Divoky V; Wierda WG; Andreeff M; Dong L; Hayes K; Verstovsek S; Kantarjian HM; Beran M
Cancer; 2004 Apr; 100(7):1459-71. PubMed ID: 15042680
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
